PRESS RELEASE

GeneSnap Version 7.02

Syngene has updated its image acquisition software, GeneSnap Version 7.02, which is available free of charge to GeneSnap customers.

This software has three new features - effective pixels, focus indicator bar and auto focus configuration settings - to help users produce focused gel or blot images, which can be used with G:BOX systems.

Effective pixels increase the resolution of the system by up to four times and the focus indicator bar allows users to see how precisely focused their image is.

Once researchers are happy with their gel image, and if they have a feedback lens, they can add their focus setting to the new auto focus configuration now in GeneSnap, so that each time they view a similar gel or blot they can recall the details to guarantee they generate reproducible, high quality images in seconds.

The auto focus configurations also hold all lighting, filter, effective pixel and exposure settings.

The new GeneSnap software will come as standard with all new Syngene G:BOX systems and existing GeneSnap customers can download the software, free of charge, from Syngene's website. The upgraded version can configure itself to adapt to the lighting and filter options installed on each G:BOX system.

Company: 
Feature

Gemma Church finds out how astronomers are using simulations to investigate the extremities of our universe

Feature

Turning data into scientific insight is not a straightforward matter, writes Sophia Ktori

Feature

The Leibniz Supercomputing Centre (LRZ) is driving the development of new energy-efficient practices for HPC, as Robert Roe discovers

Feature

William Payne investigates the growing trend of using modular HPC, built on industry standard hardware and software, to support users across a range of both existing and emerging application areas

Feature

Robert Roe looks at developments in crash testing simulation – including larger, more intricate simulations, the use of optimisation software, and the development of new methodologies through collaboration between ISVs, commercial companies, and research organisations